Triheptanoin: all 28 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyRecruitingNCT06340685Phase 1
- A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)CompletedNCT03506425Phase 1/2Results posted
- Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1DCompletedNCT03301532Phase 2Results posted
- Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)CompletedNCT03181399Phase 2Results posted
- Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)TerminatedNCT02960217Phase 3Results posted
- Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)TerminatedNCT02599961Phase 2Results posted
- Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin StudiesCompletedNCT02214160Phase 2Results posted
- An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeCompletedNCT02036853Phase 2Results posted
- Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)CompletedNCT02018315Phase 1Results posted
- Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)CompletedNCT01993186Phase 2Results posted
- A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)CompletedNCT01886378Phase 2Results posted
- Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington DiseaseCompletedNCT01882062Phase 2Results posted
- Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation DisorderCompletedNCT01379625Phase 2Results posted
- Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)WithdrawnNCT07097311Phase 2
- Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)WithdrawnNCT06067802Phase 2
- A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODActive, not recruitingNCT05933200Phase 3
- Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of AnaplerosisCompletedNCT04513002Phase 2
- Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type ICompletedNCT03665636Early Phase 1
- The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With GlycogenosesCompletedNCT03642860Phase 2
- Treatment Development of Triheptanoin (G1D)CompletedNCT03041363Phase 1
- Triheptanoin in Mc ArdleCompletedNCT02919631Phase 2
- A Pilot Trial of Triheptanoin for the Preventive Treatment of MigraineStatus unknownNCT02784847Early Phase 1
- Treatment of Mitochondrial Dysfunction in Rett Syndrome With TriheptanoinStatus unknownNCT02696044Phase 2
- The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)CompletedNCT02432768Phase 2
- Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of ChildhoodCompletedNCT02408354Phase 2
- Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation DefectsWithdrawnNCT02201368Phase 3
- Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)WithdrawnNCT02021526Phase 1/2
- Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency SyndromeStatus unknownNCT02000960Phase 2